Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 3, May-June, p. 449–453

doi: 10.17219/acem/62215

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Decreased sL-selectin serum levels in sleep apnea syndrome patients with cardiovascular diseases

Monika Kosacka1,A,B,C,D,E,F, Irena Porębska1,B,C,D,E,F, Renata Jankowska1,E,F

1 Department of Pulmonology and Lung Cancer, Wroclaw Medical University, Poland

Abstract

Background. Obstructive sleep apnea syndrome (OSA) is a common disorder associated with an increased risk of cardiovascular diseases.
Objectives. sL-selectin is an adhesion molecule released from the surface of leukocytes as they are activated and may inhibit leukocyte attachment to the endothelium. The aim of this study was to evaluate sL-selectin serum levels in OSA patients with cardiovascular diseases.
Material and Methods. A total of 163 OSA patients were enrolled in the study. The mean age was 55.41 ± 8.63 years and the mean AHI (apnea hypopnea index) was 35.02 ± 22.28/h. A control group was composed of 59 healthy subjects. All subjects underwent a nocturnal respiratory polygraphy. sL-selectin serum levels were measured using the enzyme-linked immunosorbent assay (ELISA) method.
Results. sL-selectin serum levels were significantly lower in OSA patients than in the control group (1080.02 ± 175.29 vs 1350.73 ± 569.75 ng/mL, p < 0.05). In addition, there was a negative correlation between sL-selectin levels and AHI and DI and a positive correlation between sL-selectin levels and mean and minimum saturation. sL-selectin levels were lower in OSA patients with cardiovascular diseases than in those without co-morbidities. We also found that sL-selectin correlated positively with HDL-cholesterol (high density lipoprotein) and negatively with uric acid and CRP (C-reactive protein).
Conclusion. Our work, together with observations relating to other diseases and experimental studies, suggests that lower sL-selectin levels could play a role in an increased risk of cardiovascular complications in sleep apnea syndrome. However future studies are needed to understand the role of sL-selectin in sleep apnea syndrome.

Key words

cardiovascular risk, sleep apnea, P-selectin

References (25)

  1. Lurie A. Metabolic disorders associated with obstructive sleep apnea in adults. Adv Cardiol. 2011;46:67-138.
  2. McNicholas WT, Bonsigore MR, Management Committee of EU COST ACTION B26. Sleep apnoea as an independent risk factor for cardiovascular disease: Current evidence, basic mechanisms and research priorities. Eur Respir J. 2007;29(1):156-178.
  3. Akinnusi ME, Paasch LL, Szarpa KR, Wallace PK, El Solh AA. Impact of nasal continuous positive airway pressure therapy on markers of platelet activation in patients with obstructive sleep apnea. Respiration. 2009;77(1):25-31.
  4. Lavie L, Lavie P. Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link. Eur Respir J. 2009;33(6):1467-1484.
  5. El-Solh AA, Mador MJ, Sikka P, Dhillon RS, Amsterdam D, Grant BJ. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest.2002;121(5):1541-1547.
  6. Barkhausen T, Krettek C, van Griensven M. L-selectin. Adhesion, signaling and its importance in pathologic posttraumatic endotoxemia and non-septic inflammation. Exp Toxicol Pathol. 2005;57(1):39-52.
  7. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J. 1995;9(10):866-873.
  8. Wedepohl S, Beceren-Braun F, Riese S, et al. L-selectin – a dynamic regulator of leukocyte migration. Eur J Cell Biol. 2012;91(4):257-264.
  9. Schleiffenbaum B, Spertini O, Tedder TF. Soluble L-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol. 1992;119(1):229-238.
  10. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol. 1999;87(1):10-14.
  11. Cofta S, Wysocka E, Dziegielewska-Gesiak S, et al. Plasma selectins in patients with obstructive sleep apnea. Adv Exp Med Biol. 2013;756:113-119.
  12. Li YZ, Zhang WR, Wang TC, Lu HX, Wang Y, Wang X. The role of adhesion molecules in the pathogenic mechanisms of hypertension in obstructive sleep apnea-hypopnea syndrome. Zhonghua Jie He He Hu Xi Za Zhi. 2004;27(8):511-514.
  13. Mastej K, Adamiec R. Serum level of sL-selectin and leukocyte surface expression of L-selectin in patients with type 2 diabetes. Przegl Lek. 2011;68(3):140-145.
  14. Simundic AM, Basic V, Topic E, et al. Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med. 2004;27(2):86-92.
  15. Stengel D, Bauwens K, Keh D, et al. Prognostic value of an early soluble L-selectin (sCD62L) assay for risk assessment in blunt multiple trauma: A meta-analysis. Clin Chem. 2005;51(1):16-24.
  16. Haught WH, Mansour M, Rothlein R, et al. Alternations in circulating intercellular adhesion molecule-1 and L-selectin: Further evidence for chronic inflammation in ischemic heart disease. Am Heart J. 1996;132(1):1-8.
  17. Albertini JP, Valensi P, Lormeau B, Vaysse J, Attali JR, Gattegno. Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. Diabetes Care. 1999;22(12):2044-2048.
  18. Rozenberg I, Sluka SH, Mocharla P, et al. Deletion of L-selectin increases atherosclerosis development in ApoE-/-mice. PLoSOne. 2011;6(7):e21675.
  19. Jelic S, Le Jemtel TH. Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. Trends Cardiovasc Med. 2008;18(7):253-260.
  20. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J. 2010;74(2):213-220.
  21. Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013; 99(11):759-766.
  22. Nadeem R, Molnar J, Madbouly EM, et al. Serum inflammatory markers in obstructive sleep apnea: A meta-analysis. J Clin Sleep Med. 2013;15(9):1003-1012.
  23. Ponthieux A, Herbeth B, Droesch S, Haddy N, Lambert D, Visvikis S. Biological determinants of serum ICAM-1, E-selectin, P-selectin and L-selectin levels in healthy subjects: The Stanislas study. Atherosclerosis. 2004;172(2):299-308.
  24. Cartier A, Cote M, Lemieux I, et al. Age-related differences in inflammatory markers in men: Contribution of visceral adiposity. Metabolism. 2009;58(10):1452-1458.
  25. Cerda A, Rodrigues AC, Alves C, et al. Modulation of adhesion molecules by cholesterol-lowering therapy in mononuclear cells from hypercholesterolemic patients. Cardiovasc Ther. 2015;33(4):168-176.
© Wroclaw Medical University